RecruitingPhase 1NCT07046923

A Study of LY4175408 in Participants With Advanced Cancer

A First-in-Human, Phase 1a/1b Trial to Assess the Safety, Tolerability and Preliminary Efficacy of LY4175408, an Antibody Drug Conjugate Targeting Protein Tyrosine Kinase 7-Expressing Tumor Cells, in Participants With Selected Advanced Solid Tumors

Sponsor

Eli Lilly and Company

Enrollment

240 participants

Start Date

Jul 28, 2025

Study Type

INTERVENTIONAL

Conditions

Triple-Negative Breast Cancer Carcinoma, Non-Small Cell Lung Neoplasm Metastasis Endometrial Neoplasms Small Cell Lung Carcinoma

Summary

The purpose of this study is to measure the safety and efficacy of LY4175408 in participants with selected advanced cancer. In addition, this study will evaluate how much LY4175408 gets into the bloodstream, how it is broken down, and how long it takes the body to get rid of it. Participation could last up to 4 years.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new drug called LY4175408, which is an antibody-drug conjugate (ADC) — a type of targeted therapy that delivers chemotherapy directly into cancer cells — in people with advanced cancers including non-small cell lung cancer, small cell lung cancer, endometrial cancer, and triple-negative breast cancer that have run out of standard treatment options. **You may be eligible if...** - You have confirmed advanced or metastatic non-small cell lung cancer, small cell lung cancer, endometrial cancer, or triple-negative breast cancer - You have already received all standard treatments available for your cancer, or have chosen not to continue with remaining standard options - Your general health score (ECOG) is 0 or 1 - You have measurable disease on imaging **You may NOT be eligible if...** - You have had prior treatment with a PTK7-targeting ADC that uses a topoisomerase I inhibitor payload - You have serious unresolved side effects from prior cancer treatment - You have uncontrolled brain metastases - You have serious heart disease or a history of pneumonitis/interstitial lung disease - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGLY4175408

IV infusion

Locations(25)

Stanford Cancer Center

Stanford, California, United States

Florida Cancer Specialists - Lake Nona - Sarah Cannon Research Institute

Orlando, Florida, United States

Florida Cancer Specialists - Sarasota

Sarasota, Florida, United States

The University of Chicago Medical Center (UCMC)

Chicago, Illinois, United States

Community Health Network

Indianapolis, Indiana, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

Washington University

St Louis, Missouri, United States

John Theurer Cancer Center At Hackensack UMC

Hackensack, New Jersey, United States

Columbia University

New York, New York, United States

David H. Koch Center for Cancer Care at Memorial Sloan Kettering Cancer Center

New York, New York, United States

The Ohio State University (OSU) Wexner Medical Center

Columbus, Ohio, United States

Sarah Cannon Research Institute

Nashville, Tennessee, United States

MD Anderson Cancer Center

Houston, Texas, United States

START Mountain Region

West Valley City, Utah, United States

NEXT Virginia

Fairfax, Virginia, United States

Shanghai East Hospital, Tongji University

Shanghai, China

Centre Leon Berard

Lyon, France

Institut Gustave Roussy

Villejuif, France

Kyoto University Hospital

Kyoto, Japan

National Cancer Center Hospital

Tokyo, Japan

Cancer Institute Hospital of JFCR

Tokyo, Japan

Severance Hospital, Yonsei University Health System

Seoul, South Korea

Samsung Medical Center

Seoul, South Korea

Hospital Universitario Vall d'Hebron

Barcelona, Spain

Hospital Universitario 12 de Octubre

Madrid, Spain

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07046923

Related Trials

Neoadjuvant Inhaled Azacytidine With Platinum-Based Chemotherapy and Durvalumab (MEDI4736) - a Combined Epigenetic-Immunotherapy (AZA-AEGEAN) Regimen for Operable Early-Stage Non-Small Cell Lung Cancer (NSCLC)

NCT066944541 location

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

NCT06623422231 locations

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

NCT06393374288 locations

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

NCT05633654339 locations

Study of Treatment With Sacituzumab and Zimberelimab for Patients With Lung Cancer Confined to the Chest and Previously Operated on Who Were Not Disease-free.

NCT0643163330 locations